Pharmacologic treatment of Clostridium difficile infection
Chris Gentry, PharmD, BCPS, Chief, Pharmacy Service, Oklahoma City VA Healthcare System
Upon completion of this session, participants will improve their competence and performance by being able to: Describe the epidemiology of Clostridium difficile infection. Summarize the associated morbidity of Clostridium difficile, including the propensity for recurrence. Contrast appropriate treatment strategies for Clostridium difficile infection in various settings and severities.
Professional Practice Gap:
Gap 1. New guidance on the treatment of non-severe Clostridium difficile infection and the current role of metronidazole in clinical practice.
Gap 2. Evidence for alternative strategies for minimizing Clostridium difficile infection recurrence.
Dr. Gentry has no relevant financial relationships or affiliations with commercial interests to disclose. He will be discussing experimental or off-label drugs, therapies and/or devices that have not been approved by the FDA.
For further information contact:
271-6651 ext. 54374